The 36-month beta value for SGMO is at 1.18. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SGMO is 186.71M, and currently, shorts hold a 6.82% of that float. The average trading volume for SGMO on August 06, 2024 was 11.03M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SGMO) stock’s latest price update
The stock of Sangamo Therapeutics Inc (NASDAQ: SGMO) has decreased by -11.86 when compared to last closing price of 0.87.Despite this, the company has seen a loss of -16.23% in its stock price over the last five trading days. investorplace.com reported 2024-07-24 that When small-cap biotech stocks go on a tear, many investors pay attention. Little-known company Sangamo Therapeutics (NASDAQ: SGMO ) is making waves today, with SGMO stock up more than 40% at the time of this writing.
SGMO’s Market Performance
SGMO’s stock has fallen by -16.23% in the past week, with a monthly rise of 138.11% and a quarterly rise of 38.16%. The volatility ratio for the week is 29.50% while the volatility levels for the last 30 days are 25.78% for Sangamo Therapeutics Inc The simple moving average for the last 20 days is 40.19% for SGMO’s stock, with a simple moving average of 35.26% for the last 200 days.
Analysts’ Opinion of SGMO
Many brokerage firms have already submitted their reports for SGMO stocks, with RBC Capital Mkts repeating the rating for SGMO by listing it as a “Sector Perform.” The predicted price for SGMO in the upcoming period, according to RBC Capital Mkts is $2 based on the research report published on November 03, 2023 of the previous year 2023.
BofA Securities, on the other hand, stated in their research note that they expect to see SGMO reach a price target of $1.50, previously predicting the price at $5. The rating they have provided for SGMO stocks is “Underperform” according to the report published on April 28th, 2023.
Wedbush gave a rating of “Outperform” to SGMO, setting the target price at $16 in the report published on February 27th of the previous year.
SGMO Trading at 47.80% from the 50-Day Moving Average
After a stumble in the market that brought SGMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.11% of loss for the given period.
Volatility was left at 25.78%, however, over the last 30 days, the volatility rate increased by 29.50%, as shares surge +141.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.74% upper at present.
During the last 5 trading sessions, SGMO fell by -16.23%, which changed the moving average for the period of 200-days by +33.02% in comparison to the 20-day moving average, which settled at $0.5702. In addition, Sangamo Therapeutics Inc saw 41.34% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SGMO starting from BIOGEN INC., who sale 6,000,000 shares at the price of $0.50 back on Sep 26 ’23. After this action, BIOGEN INC. now owns 17,652,466 shares of Sangamo Therapeutics Inc, valued at $3,000,000 using the latest closing price.
Stock Fundamentals for SGMO
Current profitability levels for the company are sitting at:
- -18.01 for the present operating margin
- -0.03 for the gross margin
The net margin for Sangamo Therapeutics Inc stands at -17.49. The total capital return value is set at -3.81. Equity return is now at value -167.24, with -115.20 for asset returns.
Based on Sangamo Therapeutics Inc (SGMO), the company’s capital structure generated 0.35 points at debt to capital in total, while cash flow to debt ratio is standing at -6.72. The debt to equity ratio resting at 0.54. The interest coverage ratio of the stock is 2.97.
Currently, EBITDA for the company is -92.1 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 7.19. The receivables turnover for the company is 27.14for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.71.
Conclusion
In conclusion, Sangamo Therapeutics Inc (SGMO) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
